Richard Edlin

Health economist. University of Auckland, New Zealand.

[Richard Edlin @Edlin_hecon]

@animoller @DylanReeve Always look for the checkmark. Works 100% of the time.

[Richard Edlin @Edlin_hecon]

@nationalrailenq @jappleby123 @NoContextBrits He apparently has friends. Yes, there’s a whole band on the Runcorn to Liverpool Lime Street route.

[Richard Edlin @Edlin_hecon]

@bhesmondhalgh @PRockliffe @KVBA_Music @joelycett @trussliz Just be cos it’s funny.

[Richard Edlin @Edlin_hecon]

@fcancer @overtime He still hasn’t finished

[Richard Edlin @Edlin_hecon]

@PatMcAfeeShow

[Richard Edlin @Edlin_hecon]

NZ’s approach to COVID isn't perfect, especially when using an equity lens. However, on any health economic grounds the government’s approach – given that we had the option to eliminate – seems to have served us far better. /11

[Richard Edlin @Edlin_hecon]

@gtiso Thanks for posting the ACT newsletter. The quasi-economics bits in there are really quite poor, as might be expected. I’m responding as a health economist, and where I am very concerned with their misuse of data. /1

[Richard Edlin @Edlin_hecon]

Finally, we experience an outbreak after 2 years of learning, after a vaccine has been developed, after we have had a chance to get vaccinated + boosters, and knowledge of how to treat the condition. All this makes 2022 ‘eventual COVID’ preferable to a 2020 ‘let it rip’./10

[Richard Edlin @Edlin_hecon]

Generally, where quality-adjusted life years are used you’re looking at a trade-off between costs and health. However, it’s a no-brainer when you’re looking at an improvement in health AND a cost reduction. /3

[Richard Edlin @Edlin_hecon]

@mikepaulden @Tube_of_Sand @JamesLomas88 @LVallejoTorres @djvanness @MccabeCJM @HenrikssonX Mine too!

[Richard Edlin @Edlin_hecon]

@AklTransport @richms The AT Journey Planner - your website - only contains journeys for me next week that aren't now running. This isn't "up to date", or even "relevant".

[Richard Edlin @Edlin_hecon]

@DonHusereau Yes but manage expectations. Different considerations apply for eg apparatus vs devices for individual use / economic concept of ‘rivalry’ is important. Not all trials can speak meaningfully to broader cost effectiveness of the device.

[Richard Edlin @Edlin_hecon]

@werner_brouwer Yes, if you’re looking at industry gouging esp in orphan situations & framing a debate. If a decision maker has a limited budget and is looking to invest? Here, if opp cost is based on the ability to fund something else it’s price; profits poss then an additional factor.